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As expected, rash and diarrhea were the most frequent adverse events. 
Conclusions: This interim analysis in a very large, unselected popula-
tion with advanced NSCLC in a real-practice clinical setting conﬁrms 
that erlotinib is active and well tolerated in patients with advanced 
NSCLC untreated or that have previously failed to conventional 
chemotherapy. Our data indicate that good performance status and non 
smoking history are the most convincing predictive factors for a longer 
TTP and survival in patients treated with erlotinib.
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Background: In NSCLS patients, deletions in EGFR exon 19 are 
associated with higher response rate and prolonged survival. K-ras 
substitutions in Exon 1, originally understood as mutually exclusive to 
EGFR mutations, are known as negative prognostic factor for survival 
and negative predictor of EGFR tyrosinkinase inhibitors efﬁcacy in 
NSCLC. The aim of this work was to conﬁrm above assumptions on a 
group of Czech NSCLC patients. 
Material and Methods: Cytologic and/or histologic tissue specimens 
taken from NSCLC patients treated by geﬁtinib in Early Access Pro-
gramme in Czech Republic, were processed by laser microdissection 
and screened for presence of K-ras mutations in codons 12 and 13 and 
EGFR mutations in exon 19. Therapy response and survival was corel-
lated to patients EGFR and K-ras mutation status.
Results: K-ras mutations were found in 28/252 examined patients, 
EGFR deletions in exon 19 were found in 24/279 patients. Addition-
ally, simultaneous occurence of the two mutations was detected in two 
tumour samples. The objective response to geﬁtinib was signiﬁcantly 
higher in patients with EGFR mutated tumours compared to none muta-
tion or k-ras positive status (42.8% vs 10% vs 4%). Median survival in 
EGFR mutated patients was 440 days, in patients without any mutation 
194 days and 156 days in k-ras mutated patients. The two patients har-
bouring both EGFR and k-ras mutations survived 174 and 259 days. At 
3 months from the start of geﬁtinib therapy 90% of the EFGR mutated 
patients were surviving, while 77% from non-mutated and only 57% of 
k-ras mutated. At 24 months from therapy, 15% of EGFR positive pa-
tients were surviving, 4% from k-ras and 3% from non-mutated group.
Conclusions: EGFR mutated tumours show overall better response to 
tyrosinkinase inhibitors compared to any other mutation type. K-ras 
positive patients exhibited very poor response and low survival within 
the ﬁrst 3 - 6 month of the therapy compared to non-mutated patients. 
In the long-term, however, the survival was no longer affected by the 
k-ras mutation presence. Simultaneous occurence of both, EGFR and 
k-ras mutations, was detected, but the incidence is very rare.
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Objectives: Previous studies have shown acceptable toxicity and en-
couraging activity for the combination of docetaxel (D) with oxaliplatin 
(Ox) in NSCLC. This study aims to speciﬁcally determine safety and 
efﬁcacy of this novel taxane/platinum doublet with bevacizumab (Bev), 
as ﬁrst-line treatment of advanced or recurrent and/or metastatic in che-
motherapy-naïve pts with NSCLC. We hereby report initial safety data.
Methods: The regimen to be delivered in eligible patients is as follows: 
6 cycles of D (70 mg/m2), Ox (100 mg/m2), and Bev (15 mg/kg) Q3W, 
followed by single-agent Bev (15 mg/kg) Q3w (until completion of one 
year of therapy). Patients continue treatment until evidence of disease 
progression, unacceptable toxicity, prolonged treatment delay, patient 
refusal to continue on study, or death.
Results: 25 pts (>18y) have been enrolled to-date; however, we are 
reporting information only on 14 pts, who have completed at least 2 
cycles (cy.) of therapy, and in whom complete demographic, safety, 
and other data exist at the time of this analysis. Distribution of disease 
stages (S) was: SIIIB: 2 pts (14.3%) and SIV: 12 pts (85.7%). ECOG 
PS distribution was: 0 in 10 pts, and 1 in 4 pts; there were no pts with 
PS>1. There were 2/14 (14.3%) female pts. Median age was 61.0 yrs; 
9 pts (64.3%) were < 65 yrs old. Full dose of agents were delivered in: 
12/14 pts for D and Ox, and 14/14 pts for Bev. No dose delays were ob-
served for any agent. A total of 33 cycles (cy.) were administered: 4 cy. 
in 2 pts, 3 cy. in 1 pt, and 2 cy. in 11 pts. Mean number of cy. complet-
ed was 2.4. The most frequently (>22% of pts) reported adverse events 
(AE’s) of any grade were: pain (64.3%); asthenia (57.1%); dysgeusia 
(50%); skin-related AE’s (rash or ﬂushing) (42.9%), as well as diarrhea, 
nausea, anorexia, and vomiting (35.7% each). Fourteen grade (G) 3/4 
AE’s were seen in 7 pts, including neutropenia: 4 (of which 1 was 
febrile), pneumonia: 2, sepsis: 1, GI AE’s: 4, hypertension: 1, fatigue: 
1, and broncho-esophageal ﬁstula: 1. Eight of the 14 G3/4 AE’s were 
severe (SAE’s) and occurred in 3 pts. There were 2 deaths, one due to 
disease progression, and another one due to a SAE (possibly drug-
related), occurring within 91 and 35 days from completion of the 2nd 
cy. of Rx, respectively. Of note, despite the above G3/4 AE and SAE 
proﬁles, only 2 pts required dose modiﬁcation for D or Ox, while no 
pts experienced dosing delays. Furthermore, to-date, no Bev-associated 
colonic perforations or pulmonary hemorrhages have been reported.
Conclusions: These preliminary data support feasibility of this regi-
men, as they show acceptable safety features, and will be updated at 
the time of presentation. The plan is to continue enrollment to 75 pts. 
Primary efﬁcacy endpoint is progression-free survival, while secondary 
endpoints are objective response rate and overall survival. 
N.B.: This study is sponsored by Sanoﬁ-Aventis. 
